This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Dehmer SP, Maciosek MV, Flottemesch, TJ. Aspirin use to prevent cardiovascular disease and cancer: a decision analysis. Rockville: Agency for Healthcare Research and Quality (AHRQ). AHRQ Publication No. 15-05229-EF-1. 2015
To assess the net balance of benefits and harms from routine use of aspirin for primary prevention across clinically relevant age, sex, and cardiovascular disease (CVD) risk groups.
Benefits are predicted to exceed harms among persons aged 40-69 with nonelevated bleeding risk who take aspirin for primary prevention of CVD and CRC over their lifetimes. Net benefits from routine aspirin use over a 10- or 20-year horizon are expected to be substantially smaller, and in many cases, harms may exceed benefits. Findings do not differ markedly between men and women; however, deterministic and probabilistic sensitivity analyses reveal meaningful uncertainty about the magnitude of net benefit.
Subject indexing assigned by CRD
Aspirin; Cardiovascular Diseases; Decision Support Techniques; Humans; Neoplasms
Country of organisation
An English language summary is available.
Address for correspondence
AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov
Date abstract record published